

PERMIDES Voucher Application

Terms & Conditions

July 21st 2017

Content

About PERMIDES.....	2
Submission Conditions.....	3
Application Conditions.....	3
Financial Provisions.....	4
Timeframe.....	6
Reporting	6
Confidentiality.....	7
Intellectual Property Rights and Dissemination	7
Travel Vouchers	8



This project is funded by
the European Union

About PERMIDES

It is the aim of PERMIDES to strengthen the competitiveness and foster the innovation potential of Personalized Medicine as an Emerging Industry in Europe by providing key solutions for the reconfiguration of the biopharmaceutical value chain towards a Health Economy 4.0 with a special focus on oncology (i.e. cancer treatment). In a cross-clustering approach, leading biopharma and IT clusters from three countries (Austria, Germany and Norway) are creating novel cross-sectoral collaborations between SMEs to address innovation barriers in the biopharma sector via cutting-edge IT solutions. As a cross-cutting industry, the ICT and software sector is an enabler of innovation in many industries and therefore provides a broad knowledge base of processes and best practice solutions in diverse industrial contexts and business environments.

PERMIDES is creating a collaboration space consisting of workshops and a semantic online matchmaking portal (PERMIDES Platform), complemented by matchmaking events that will allow biopharma enterprises to identify a suitable ICT partner matching the needs of the biopharma partner. In a second step, the biopharmaceutical SME and the ICT partner can apply for a joint innovation project supported by an innovation voucher to tackle an innovation barrier in the value chain. Follow-up coaching and transfer activities by the cluster organizations will maximize the impact of these collaborative innovation projects.

Project Facts

Project Acronym:	PERMIDES
Project Title:	Personalized Medicine Innovation through Digital Enterprise Solutions
Project Reference:	H2020-INNOSUP-1-2015, Grant agreement no: 691546
Project Type:	Cluster facilitated projects for new value chains
Project Duration:	24 months from 01.09.2016 to 31.08.2018
Budget:	€ 4.838.318 (EC Funding)
Web:	http://www.permides.eu/

Project Partners

- Software Cluster c/o CyberForum e.V. (Coordinator) (Germany)
- Cluster for Individualized Immune Intervention (Ci3) e.V. (Germany)
- Oslo Cancer Cluster S.A (Norway)
- Smart Innovation Norway AS (Norway)
- Oncotyrol Center for Personalized Cancer Medicine GmbH (Austria)
- IT-Cluster - Business Upper Austria OÖ Wirtschaftsagentur GmbH (Austria)
- intelligent views gmbh (Germany)
- NETSYNO Software GmbH (Germany)

Contact (Coordinator)

Tamara Högler | CyberForum e.V. | Germany

Phone: +49 72160289729 | Email: hoegler@cyberforum.de



This project is funded by
the European Union

Submission Conditions

- Applications for PERMIDES Vouchers can only be submitted via the PERMIDES Platform using the provided templates.
- The applicants have to be registered on the PERMIDES Platform.
- The applicants must have SME status according to the SME definition of the European Union¹.
- The applicants are headquartered in one of the EU Member States² or Associated Countries³ but in no other countries.
- For consultancy and innovation voucher applications one applicant has to be from the biopharmaceutical sector (e.g. biotech/medtech companies, diagnostics companies, CROs, biobank companies, bioinformatics companies) and is considered as beneficiary. The other applicant(s) has (have) to be from the IT sector and is (are) considered as service provider(s). Companies with expertise in the biopharmaceutical as well as IT sector (referred to as “hybrid” such as bioinformatics companies) may, in distinct applications, either act as beneficiary or as service provider depending on the project context.

Application Conditions

- Innovation voucher applications must represent a joint project between one beneficiary SME from the biopharmaceutical sector and at least one SME from the IT sector acting as service provider. Additional partners such as large companies, research organisations, universities, clinics or incubators can participate in the innovation project (and thus can be mentioned in the application) but are not eligible for PERMIDES funding.
- Consultancy voucher applications must represent a joint action between one beneficiary SME from the biopharmaceutical sector and one SME from the IT sector as service/consulting provider.
- Applications for consultancy and innovation vouchers must address innovation barriers/challenges of the biopharmaceutical value chain by means of digitalization solutions provided by IT SMEs. Note that consultancy received via consultancy vouchers can aim at providing information to establish the background knowledge needed for an innovation voucher application.
- An innovation project must meet the following criteria in order to get funded via PERMIDES vouchers:
 - The project aims at new products, processes or technical services for personalized medicine which, with their functions, parameters or characteristics exceed the existing products, processes or technical services for the applying biopharmaceutical company and are based on the international state-of-the-art of science and technology.
 - The project increases the technological performance level of the applying biopharmaceutical company or its innovation competence.

¹ http://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_de

² http://ec.europa.eu/research/participants/data/ref/h2020/other/wp/2016-2017/annexes/h2020-wp1617-annex-a-countries-rules_en.pdf

³ http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/hi/3cpart/h2020-hi-list-ac_en.pdf



- The project strengthens the competitiveness of the applying biopharmaceutical company on a demanding level of innovation and thus accelerates and improves the product development capabilities, opens up new market opportunities and/or creates/secures jobs.
- The project should not create risks for the daily business of the applying SMEs.

Financial Provisions

- In a consultancy or innovation project a SME from the biopharmaceutical sector as beneficiary receives service(s) from IT SME(s) and only the costs incurred and invoiced by IT SME(s) are eligible for direct funding via PERMIDES vouchers.
- The eligible costs include the personnel costs and depreciation costs of equipment, infrastructure or other assets necessary for the project incurred and invoiced by the participating IT SME(s). The sum of costs of specific investments such as hardware or licences necessary for an innovation project shall not exceed 50% of the total costs. The sum of travel costs for a consultancy project shall not exceed 30% of the total costs.
- The total amount of financial contribution made by PERMIDES shall not exceed in any circumstances the maximum amounts indicated below:

<i>Type</i>	<i>Value (€) per voucher</i>	<i>Purpose</i>	<i>Target Group (limits €)</i>
Consultancy Voucher	up to 5.000	A biopharma SME can make use of an individual consultation by an IT SME, regarding a specific challenge in its value chain that could be improved via IT. A biopharma SME can apply for multiple Consultancy Vouchers. The cumulative amount available via Consultancy Vouchers per biopharma SME is limited to 12.000€.	Biopharma SMEs (each SME limited to 12.000)
Innovation Voucher	up to 60.000	A biopharma SME will receive a customised IT solution adapted to its specific competitive situation. A biopharma SME can apply for multiple Innovation Vouchers. The cumulative amount available via Innovation Vouchers per biopharma SME is limited to 60.000€.	Biopharma SMEs (each SME limited to 60.000)
<p>The overall maximum funding available for any SME from the biopharmaceutical sector is 60.000 Euro (= sum of all vouchers awarded to this beneficiary)!</p> <p>Any funding received by a SME in form of PERMIDES Travel Vouchers (see below) will be deduced from the overall amount of funding available for this SME.</p>			

- IT SMEs as service providers are not restricted to the overall maximum funding threshold indicated above and thus can participate in multiple consultancy or innovation projects with distinct beneficiaries with a total cumulative value exceeding 60.000 Euro.
- At project half-time of the innovation project: PERMIDES will pay up to 50% of the awarded voucher sum directly to the service providing IT SME(s) upon evaluation of the interim report of the respective innovation project (see section reporting).



- At the end of the respective innovation project: remaining costs incurred and invoiced by the participating IT SME(s) not exceeding the costs applied for will be paid by PERMIDES directly to the service providing IT SME(s) upon evaluation of the final report (see section reporting).
- At the end of the consultancy project: costs incurred and invoiced by the participating IT SME(s) not exceeding the costs applied for will be paid by PERMIDES directly to the service providing IT SME(s) upon evaluation of the final report.
- Any payment will be made in EURO.
- Expenditure incurred before or after the duration of the project is ineligible for remuneration.
- Costs incurred for the implementation of the project must be used for the sole purpose of achieving the objectives of the project and its expected results, in a manner consistent with the principles of economy, efficiency and effectiveness.
- Note that project partners are advised to set up internal contracts regulating their cooperation. PERMIDES will not be responsible for paying any costs applied for and incurred by the project partners in case of non-compliance with the terms and conditions of the PERMIDES funding scheme.
- Note that submission of an application does not constitute an entitlement for funding.
- The recipients of the financial support from PERMIDES must ensure that the Commission, the European Anti-fraud Office (OLAF) and the Court of Auditors (ECA) can exercise their powers of control, on documents, information, even stored on electronic media, or on the final recipient's premises as detailed in Article 22 and 23 of the Annotated Model Grant Agreement of the H2020 Programme:
http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/amga/h2020-amga_en.pdf



Timeframe

- The timeframe of the proposed project must not exceed 6 months. Irrespective of its start date, the end date of any project cannot be later than June 15th 2018.
- The PERMIDES call for voucher applications will open 15th March 2017 (12:00 CET) and closes November 15th 2017 (12:00 CET). Applications can be made continuously throughout this period.
- Evaluation cut-off dates for innovation voucher applications will be: May 15th 2017 (24:00 CET) and October 10th 2017 (12:00 CET).
- After each evaluation cut-off date, the innovation project proposals that have been submitted before will be reviewed by the PERMIDES consortium and an external reviewers board. Successful projects will be awarded within max. 3 months after the cut-off date.
- Consultancy voucher application will be evaluated continuously by the PERMIDES consortium throughout the whole call period; no interim cut-off dates apply.
- If an application has been evaluated positively and a voucher is granted, the applicants will need to sign a formal contract with PERMIDES coordinator CyberForum in order to start the project.
- If an application has not been evaluated positively, the PERMIDES consortium will provide feedback and re-application is possible if within the call period.

Reporting

- The recipients of the financial support in form of an innovation or consultancy voucher have to hand in the following reports:
 - A short online interim report* on project performance and a financial report* regarding the down payment using a template provided via the PERMIDES Platform at the latest 15 days after half of the project time has passed (only for innovation vouchers).
 - A concise final project performance report and a financial report* (based on the interim report in case of innovation projects) using templates provided via the PERMIDES Platform at the latest 15 days after the project is finished.
- * Reports will be generated in an online form provided via the PERMIDES Platform. Data existing prior to reporting (from registration, application, interim report) will be automatically integrated.
- During the complete runtime of an innovation project, the project partners have to inform the PERMIDES consortium immediately about occurring problems which may endanger the success of the project.



Confidentiality

- Note that signing a Non-Disclosure Agreement (NDA) is optional and that it is the own responsibility of each partner of the respective innovation or consultancy project to protect sensitive information! A sample NDA can be found at: <https://www.iprhelpdesk.eu/Mutual%20Non%20Disclosure%20Agreement>
- Applications selection and evaluation will be performed under appropriate ethical conduct and will respect the confidentiality of the information received.
- The personal data collected will be processed and data privacy handled in accordance to the terms of use of the PERMIDES platform.
- By participating, the applicant agrees on the storage and use of its personal data for the execution of the PERMIDES objectives and work plan. The PERMIDES consortium commits to confidentially handle personal data except the call results which contain the following information:
 - Information about successful innovation voucher applications that will be made publicly available **before** the end of the project contains: project title, names of project partners and short project description (as provided by the applicant in the application template).
 - Information about successful innovation/consultancy voucher projects that will be made publicly available **after** the end of the project: project title, names of project partners, awarded funding and updated short project description (as provided by the project partners in the final project report).

Intellectual Property Rights and Dissemination

- The applicants will be free to **set up internal contracts** regarding Intellectual Property Rights, use and dissemination of the results generated by the project teams through the funding obtained via PERMIDES Innovation Vouchers. For details on rights and obligations related to results, the project teams can refer to Chapter 4 (Section 3) of the Annotated Model Grant Agreement of the H2020 Programme: http://ec.europa.eu/research/participants/data/ref/h2020/grants_manual/amga/h2020-amga_en.pdf
- For dissemination and use of results generated through the financial support from PERMIDES, the recipients must credit the PERMIDES project through proper citation. For example: "*This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 691546*".



Travel Vouchers

- Travel voucher applications can only be submitted by individual SMEs according to the [SME definition](#) of the EU and headquartered in one of the [EU Member States](#) or [Associated Countries](#) but in no other countries either from the biopharmaceutical or IT sector for travelling to dedicated PERMIDES events. These events will be announced on the PERMIDES website. Provision of a travel voucher and subsequent reimbursement are pending approval by the PERMIDES consortium.
- The total amount of financial contribution made by PERMIDES shall not exceed in any circumstances the maximum amounts indicated below:

Type	Value (€) per voucher	Purpose	Target Group (limits €)
Travel Voucher	up to 1.800 (international) up to 200 (national)	Supporting SMEs in taking part in dedicated PERMIDES events such as matchmaking events and workshops. Travel Vouchers are differentiated between national and international travels. A biopharma or IT SME can apply for multiple Travel Vouchers. The cumulative amount available via Travel Vouchers per SME is limited to 6.000€. A Travel Voucher will be awarded to a company, not to a single employee of a company. If a company sends more than one employee to a project-related event, the travel costs for these employees have to be added together and applied for via one single Travel Voucher application.	Biopharma SMEs and IT SMEs (each SME limited to 6.000)
Note that granted travel vouchers are credited against the maximum funding a SME can receive via PERMIDES vouchers. The overall maximum funding available for a particular biopharma SME is 60.000 Euro!			

- The costs must be declared on actual real cost basis using a provided Travel Expense Report form within 30 working days after the specified event. Costs must be reasonable, justified and comply with the principle of sound financial management, regarding economy and efficiency. All relevant invoices must be provided as a copy. Originals must be marked with following text: *“project PERMIDES funded by the European Union under the Grant Agreement number 691546”* and be archived for at least 5 years for potential audit purposes.
- Only eligible costs will be reimbursed if they are in line with the rules of the Horizon 2020 program. Eligible costs are e.g.:
 - Costs for local transport, trains (only second class), flights (only economy-class), kilometre allowances (if not higher than the costs for a comparable train ticket)
 - Costs for accommodation
 - Conference fees up to 200 EUR.
- All amounts must be delivered in EUR. Possible currency exchange losses must be covered by the applicant.



- Note that proof of attendance is mandatory for reimbursement. SMEs need to make sure to meet a PERMIDES representative during the dedicated event to sign an attendance form.
- If a SME is specifically invited by the PERMIDES consortium to present at dedicated PERMIDES events such as a Digital Health Forum or an Awareness Raising/Dissemination event, the SME can apply for an international Travel Voucher. In this case conference registration fees of up to EUR 900 can be covered. The cost of conference registration fee shall not exceed 50% of the total costs of the travel voucher.

